Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children

Update Il y a 4 ans
Reference: GSK111535

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

This protocol posting deals with objectives & outcome measures of the booster phase. The objectives & outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00412854). This Phase IIIB study will compare GSK Biologicals' DTPa/Hib vaccine to separately administered DTPa and Hib vaccines in Chinese children 18 to 24 months of age, in terms of safety and immunogenicity.


Inclusion criteria

  • Acellular Pertussis,Diphtheria,TETANUS

Links